A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Tekijät: Liebers, Nora; Boumendil, Ariane; Finel, Hervé; Edelmann, Dominic; Kobbe, Guido; Baermann, Ben-Niklas; Serroukh, Yasmina; Blaise, Didier; Beelen, Dietrich Wilhelm; Solano, Carlos; Itälä-Remes, Maija; van Meerten, Tom; Choi, Goda; Schmidt, Susanne Anna Christine; Kröger, Nicolaus; Byrne, Jenny; Tudesq, Jean-Jacques; Ossami, Saidy Anna; Nunes, Ana; Siddiqi, Rubina; Baro, Elande; Zheng, Dan; Kloos, Ioana; Dreger, Peter; Sureda, Anna; Glass, Bertram; Dietrich, Sascha
Kustantaja: American Association for Cancer Research (AACR)
Julkaisuvuosi: 2025
Journal: Blood Cancer Discovery
Tietokannassa oleva lehden nimi: Blood Cancer Discovery
Vuosikerta: 6
Numero: 3
Aloitussivu: 182
Lopetussivu: 190
ISSN: 2643-3230
eISSN: 2643-3249
DOI: https://doi.org/10.1158/2643-3230.BCD-24-0178
Verkko-osoite: https://doi.org/10.1158/2643-3230.bcd-24-0178
Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 r/r MCL patients aged ≥50 years treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (out of 272) r/r MCL patients who underwent alloHCT using data from the EBMT registry. Median follow-up time was 36.5 and 34.1 months for the brexu-cel and matched alloHCT cohort, respectively. Brexu-cel patients had a significantly higher overall survival (OS, 81.3% vs 59.2%, HR: 0.39, p=0.004) and lower non-relapse mortality (3.6% vs 21.2%, p=0.015) one year after treatment. Chronic graft-vs-host disease occurred in 26.9% of alloHCT patients within the first year. However, long-term progression-free survival and OS remain comparable. Despite limitations of this non-randomized study, it indicates a superior safety profile for brexu-cel in r/r MCL.
Significance: Patients aged ≥50 years with r/r MCL had superior OS and lower nonrelapse mortality 1 year after receiving brexu-cel compared with alloHCT. However, the long-term PFS and OS are similar for both treatments. Individual risk–benefit evaluation is essential to guide optimal treatment decisions.
Julkaisussa olevat rahoitustiedot:
Funding Group:
Award Group:
Funder(s): National Center for Tumor Diseases (NCT) Heidelberg
Award Id(s): Heidelberg School of Oncology (HSO2)
Principal Award Recipient(s): N. Liebers
Award Group:
Funder(s): Hairy Cell Leukemia Foundation (HCLF)
Principal Award Recipient(s): S. Dietrich
Award Group:
Funder(s): Else Kroener Fresenius Foundation
Principal Award Recipient(s): S. Dietrich
Award Group:
Funder(s): Heidelberg Research Centre for Molecular Medicine (HRCMM)
Principal Award Recipient(s): S. Dietrich
Award Group:
Funder(s): Bundesministerium für Bildung und Forschung (BMBF)
Award Id(s): e:med junior grant
Principal Award Recipient(s): S. Dietrich
Award Group:
Funder(s): Deutsche Forschungsgemeinschaft (DFG)
Award Id(s): SFB873
Principal Award Recipient(s): S. Dietrich
